{"name":"Sobi, Inc.","slug":"sobi-inc","ticker":"","exchange":"","domain":"sobi.com","description":"Sobi, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases. The company's portfolio includes marketed products such as Avatrombopag, which is used to treat thrombocytopenia.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Avatrombopag Oral Tablet","genericName":"Avatrombopag Oral Tablet","slug":"avatrombopag-oral-tablet","indication":"Thrombocytopenia in patients with chronic liver disease undergoing invasive procedures","status":"marketed"}]}],"pipeline":[{"name":"Avatrombopag Oral Tablet","genericName":"Avatrombopag Oral Tablet","slug":"avatrombopag-oral-tablet","phase":"marketed","mechanism":"Avatrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes.","indications":["Thrombocytopenia in patients with chronic liver disease undergoing invasive procedures","Chronic immune thrombocytopenia (ITP)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNWEdDN3MzNHQyakxCM1JfUGZ4WllmNFFvWG5vSGFseHZ1T1hCNm94T05LYm5YVUVORXRqdnE2TzBsaFg1LUh0Y1lxRXV5cWE1MXhvX01tdEsyU2dzejBHLVFTT0hQQTJUM3plSmdfc3QxVFlieFA2Q2xNSGtKcWFWZ1RySHhCci05UHQ0eWJUMFFxZWxw?oc=5","date":"2025-12-15","type":"deal","source":"Contract Pharma","summary":"SOBI Agrees to Acquire Arthrosi Therapeutics - Contract Pharma","headline":"SOBI Agrees to Acquire Arthrosi Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQaTFjYTNtY3lodC1tOVhhRXJsZjRoX1RrUXJPSUNMbVdIamtvSW9sWUpyRC1HN2dLbGJTYTY5Mm83WmxJem4tZkZIbEFYMEtCSURCMkNKb08tSDdEaVc3YnZlZ1dyRXRuRTVZOFdYN25IYzFQSE0teDU1Q2ROWHZHLW1NWmF1emlzUVVJTnNzT3JnWlJwTzNYSTF3eUNZSGo3ejVabDI4ZVZWa2x5YmpoSGVNdzNua2M2c3dxdTBvRjdEbFQzLUtNNU5uUVpaX3JmRzBXdm9XMVI3WU9rcmF0TVBXVUZnY0k?oc=5","date":"2025-12-15","type":"deal","source":"PR Newswire","summary":"Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout - PR Newswire","headline":"Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5MeDVNNHAzR3dRR0ozZjBaRHVMWUNIOUZoUjIwYXdkSDRfdXpiNnRQRlNJWkUySGlXUUFQeUx4bWRmNDhhOVdGdG9fa3hEOTZiYmlXaDRFZDZxVXJFamtFZ1FuS05JNG9kX1dwVnhweTY?oc=5","date":"2025-12-15","type":"pipeline","source":"pharmaphorum","summary":"Sobi pays $1.5bn for Arthrosi to grow in gout - pharmaphorum","headline":"Sobi pays $1.5bn for Arthrosi to grow in gout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOcUE0MWFqWFZIOFFlRklpNGttcWtDUy1CcldEUlFQYnpGQ21LTW5zMVM2SWNQYTN4QnBRQl9wbHRmdk9yZDJoRmFwRFVyTVZQOGxJLUE3X1cyeUVMU0x6alhTaDZURjhZTEd0aDl4MHRndnNqODJoaU9zSlBUb3p2b1BaVmswOFR6QjBfRUJfQ1Z2dTU0eXl2RXZCV0hzQnRRVUNGUzJaYjRkNXExZnMzb3BRUEhpVEhDVEtGeG1henhFNDA0dWk2R2t0d3pKbEhZRVliZ2h6eXF1dkxsQnV4emlDLTdHYmp4UGhIYUtUQlRqbEZGT2JERnBLejVYajh1UjgzcldqekF3Z3VmR0FOT1lsWnZ3TUx5RmplcVQ5MWdZWTFVRFE?oc=5","date":"2025-12-15","type":"pipeline","source":"BioSpace","summary":"Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion. - BioSpace","headline":"Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNYk1DMndiUkgtMUpYaVhMUkdMeGRXS3VSY1JWZ29IYVljTV9UYjlOZWhvQ1JxMW9pcVc1WWNTTUZMZ21rWEk2UFBDZF9sbTJwRU1NSjBqM3lfUU1yVmNnVkREMnZVcklpbmxQcUQ0WUpDMWJycl8wMlc5bnhwNHFSblYydE5FZw?oc=5","date":"2025-12-14","type":"deal","source":"BioPharma Dive","summary":"Sobi snaps up gout drug in $950M deal for startup Arthrosi - BioPharma Dive","headline":"Sobi snaps up gout drug in $950M deal for startup Arthrosi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPN1N0cERWRWdNTHpZM3lJS3ZrOTZqVjA3SXY2S2tEb1g2VlNENGd6Z2pjb19USVpWaFdjMy10SGU0WXpsU3o4WWNuRlA4TzJSZFFZTnAzZ0RoMW9EWnlBZlM0SUEwZHFBZ3oxSjFGN1hxak9ZVzVHNFYzRklHeDlCbmhCUTE2VnNTeHVHaVVzVVNHcGhkM295RWg2QWhvRnVEbnRGMGZ0aXV0dnlqUlBUZm02b0M?oc=5","date":"2025-09-23","type":"pipeline","source":"Fierce Pharma","summary":"Sobi surpasses Roche in rare disease patient groups' reputation rankings - Fierce Pharma","headline":"Sobi surpasses Roche in rare disease patient groups' reputation rankings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNQTlsTV9FN0dfZi1RY3BSdTByYUJ5Q1VlT045LVB6ZC00WkhxemlUcWJSX09JbVRCeEx1WGZZN3pHUlhLYy03TnFoOEJobmxWUk82WEU1UTNuY0lGQ3VYMzFwajF0SG94bDR4V2x2ZlFJcWRJeU9kMXJLVExrSXU3ZU9sUVgzWDRxb29HVHZqTTFMRU9TQ1c5elFhZmIzSVBnU18tczBSM2otTjFRY0ZUeHFB?oc=5","date":"2025-07-16","type":"pipeline","source":"Bloomberg.com","summary":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’ - Bloomberg.com","headline":"Swedish Drugmaker Sobi Doesn’t See Pharma Tariffs as ‘Imminent’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1yOXVBREZKNGVOdW1VRFlnSTVkSjdKOGhMRG54X0pTMkpza3lZU3VacEs1aUJvWG94T0RhOW1vdXJlem5QVnc0N2VFMC01UlBiX2RjUFFxbGhuSE9ITzRfZWFYS3pGWFdISkhrRjl1THhGS21VRF9manRZcWtVMXc?oc=5","date":"2025-07-08","type":"pipeline","source":"Yahoo Finance","summary":"Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - Yahoo Finance","headline":"Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQU2Z1b3JRTFFEMjRubDNPTTZ5amY4NU9reVFBY1lUR0l3UzJUMkhQZXhpWE1BMW1ZdW9XMUZhSzFFXzUydmNPMWc4QldFbE9xTC04dHB1Q1duMXFZYkVnVnJMVHNuellWUjlnZ3V1TEFIRExScS1UZkk4bHJjQjRkdmFPV1Uyaks2dC0w?oc=5","date":"2025-06-06","type":"trial","source":"The Pharma Letter","summary":"Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter","headline":"Sobi and Apellis data underscore Aspaveli potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPUDVlbDZadXlEUnpxZFdKSUYzVmIyUmdyUXNyeFgwLTJwbjV0cmV5STM1QzBnLWhCX2JrSlF5M2NKa3VzUXZOVlF5MThLU1lUWU5maGk1SGh3a2dhU3BHMlB5N3RTYTljUUhzb1JBY3hiVXNfaHNod3pSTUNuUGtlTHZIYXJkUUZTTHJoX19Jbw?oc=5","date":"2025-03-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Ionis and Sobi agree on olezarsen commercialisation - Pharmaceutical Technology","headline":"Ionis and Sobi agree on olezarsen commercialisation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNcWFRV21FOHA0VVo1WExMV2tvWXN5TEJlSW1GTnZzUUlKRVM4RWktdnpIZkxfTG5ERm82WTBoVktpSXQzYlZCUml2WGtKVU9TNVF0U1hWdnpjY3hRdkg0czl2TWloVUEyR0tyUmhMQkpfWURXYlZKSU5BWllFYzAybTV4Q0NyWXpFUWtIeWJoRW8?oc=5","date":"2020-10-27","type":"deal","source":"Latham & Watkins LLP","summary":"Latham & Watkins Advises Sobi on Strategic Licensing and Collaboration Agreement with Apellis Pharmaceuticals Inc. - Latham & Watkins LLP","headline":"Latham & Watkins Advises Sobi on Strategic Licensing and Collaboration Agreement with Apellis Pharmaceuticals Inc. - Lat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPd2UtbkpFN3phbmZuamJUTm9LdEJWcmFyR0hraDVIenZseUMtdUJaaVRhY3hBLVU1eWFhUHZCd0RoYjVzWWpRaXlXVWZ0V09ITEkxeXJPT014SDdmWmw4QU9GbHIwN0hIMzhUQVVUb0tsbGhrRHlUOW1Qbzd1d2wxWFF5LUdxcHo0WjV2dUtxNWVRZEFsMWUxVnNjS3YxUHFDdm9hWkhWTVVmWHRkR1BRRQ?oc=5","date":"2018-01-25","type":"pipeline","source":"sobi.com","summary":"Sobi Names Holly May Vice President of Sales and Marketing in United States - sobi.com","headline":"Sobi Names Holly May Vice President of Sales and Marketing in United States","sentiment":"neutral"},{"date":"2004-08-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2004-04-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2004-02-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}